
Sign up to save your podcasts
Or


Send us Fan Mail
Javonte Maynor joins family doctor and medical marijuana expert Dr. Erich Schramm to discuss the changing space of marijuana research and medical marijuana in the United States. The duo discuss the frustration with politics entering the medical space when it comes to marijuana, and how changing administrations can delay research. The two get into the nuts and bolts of marijuana research, including the hoops needed to perform research, conditions being treated, and a study that may be coming soon. Dr. Schramm also explains his role prescribing marijuana for the last several years and what that entails from a legal standpoint. The two then imagine what may happen to these processes if marijuana is rescheduled from a Schedule 1 to a prescribable Schedule 3 drug; including to dispensaries, the pharmaceutical industry, and current prescribing doctors.
Be a part of advancing science by participating in clinical research.
Have a question for Dr. Koren? Email him at [email protected]
Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube
Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn
Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com
Music: Storyblocks - Corporate Inspired
Thank you for listening!
By Dr. Michael Koren5
77 ratings
Send us Fan Mail
Javonte Maynor joins family doctor and medical marijuana expert Dr. Erich Schramm to discuss the changing space of marijuana research and medical marijuana in the United States. The duo discuss the frustration with politics entering the medical space when it comes to marijuana, and how changing administrations can delay research. The two get into the nuts and bolts of marijuana research, including the hoops needed to perform research, conditions being treated, and a study that may be coming soon. Dr. Schramm also explains his role prescribing marijuana for the last several years and what that entails from a legal standpoint. The two then imagine what may happen to these processes if marijuana is rescheduled from a Schedule 1 to a prescribable Schedule 3 drug; including to dispensaries, the pharmaceutical industry, and current prescribing doctors.
Be a part of advancing science by participating in clinical research.
Have a question for Dr. Koren? Email him at [email protected]
Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube
Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn
Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com
Music: Storyblocks - Corporate Inspired
Thank you for listening!

228,383 Listeners

43,528 Listeners

9,622 Listeners

11,865 Listeners

8,748 Listeners

3,457 Listeners

12,633 Listeners

1,688 Listeners

19,524 Listeners

12,143 Listeners